MoonLake Immunotherapeutics Faces Class Action After 90% Stock Plunge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Source: Globenewswire
- Lawsuit Initiation: A class action has been commenced against MoonLake Immunotherapeutics, alleging misleading statements during the period from March 10, 2024, to September 29, 2025, resulting in a nearly 90% stock plunge on September 29, 2025.
- Drug Efficacy Failure: MoonLake's Phase 3 trial results announced on September 28, 2025, revealed that its drug candidate sonelokimab failed to match the efficacy of competitor BIMZELX, which analysts labeled as a “disastrous result.”
- Legal Risk Concealment: The lawsuit against Cepton, Inc. alleges that during the period from July 29, 2024, to January 6, 2025, the company failed to disclose tax fraud and bribery, leading to significant investor losses.
- Investor Damages: As the true details emerged, shareholders of Cepton faced severe damages, with the lawsuit seeking compensation, highlighting significant deficiencies in corporate governance and transparency.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
